Blog

Ariana Resources (LSE:AAU) has commenced operations at its Tavşan Heap-leach Project in Türkiye after receiving the final operational permits. This marks a key milestone for the company, with initial gold production expected to begin within the current quarter. Operated by Zenit Madencilik San. ve Tic. A.S.—in which Ariana holds a 23.5% stake—the project is set to significantly boost the company’s overall gold output and reinforce its market position amid strengthening gold and silver prices. The Tavşan Project has an estimated mine life of eight years, with ongoing exploration suggesting additional resource expansion potential.

About Ariana Resources

Ariana Resources PLC is a mineral exploration, development, and production company with a diversified portfolio of gold assets across Europe and Africa. The company is actively involved in the Tavşan Heap-leach Project in Türkiye through its partnership with Proccea Construction Co. and Ozaltin Holding A.S. By combining strategic joint ventures and operational expertise, Ariana aims to advance sustainable gold production and deliver long-term shareholder value.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Greencore Group PLC (LSE:GNC) has reported a strong financial performance for the fourth quarter and full year of 2025, achieving 8% revenue growth driven by new business wins, product innovation, and favorable weather conditions. The company launched 130 new products during Q4 and improved profit margins through disciplined cost management initiatives. Net debt declined substantially over the year, and Greencore expects its adjusted operating profit to exceed previous forecasts.

In parallel, the company is moving forward with the planned acquisition of Bakkavor Group PLC, which remains subject to regulatory approval. The transaction is expected to broaden Greencore’s product range and strengthen its position within the UK convenience food market.

Greencore’s outlook remains positive, supported by solid financial performance and effective cash flow management, though ongoing margin improvements remain a focus area. Technical indicators suggest weak momentum, while valuation metrics indicate the stock is fairly priced. The absence of recent corporate updates limits further insight into near-term developments.

About Greencore Group PLC

Greencore Group PLC is one of the UK’s leading manufacturers of convenience foods, serving major supermarkets, travel and convenience retailers, discounters, coffee chains, and foodservice operators. The company holds strong market positions across categories including sandwiches, salads, sushi, chilled ready meals, soups, and sauces. Headquartered in Dublin, Ireland, Greencore operates 16 manufacturing facilities and 17 distribution centers, employing approximately 13,300 people nationwide.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Fiinu Plc (LSE:BANK) has completed the full drawdown of a £2 million convertible loan facility from Conister Bank Limited, providing additional working capital and supporting the continued development of its proprietary technology platform. In parallel, the company has appointed Marex Financial as a Joint Broker, succeeding SP Angel Corporate Finance LLP. These moves reflect Fiinu’s ongoing efforts to strengthen its financial foundation and strategic partnerships as it prepares for the anticipated launch of its flagship product, the Plugin Overdraft®, in the fourth quarter of 2025.

About Fiinu Plc

Fiinu Plc is a UK-based fintech company focused on developing and commercializing innovative financial technology solutions. Best known for its Plugin Overdraft®, the company aims to provide flexible, technology-driven credit alternatives designed to enhance consumer financial accessibility and improve banking efficiency.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Impax Asset Management (LSE:IPX) reported that its assets under management (AUM) held steady at £26.1 billion in the fourth quarter of its financial year, marking a slight increase compared to the start of the second half. Although the firm experienced net outflows during the period, it noted improving fund flow trends and strong inflows from clients in Europe and North America. Impax’s investment strategies delivered positive absolute returns, though performance was tempered by the dominance of AI-driven mega-cap technology stocks in global equity markets. The company reaffirmed confidence in its long-term investment approach and its competitive market positioning.

Impax Asset Management’s overall outlook is supported by strong financial fundamentals and an attractive valuation. Despite some technical caution due to bearish momentum indicators, the company’s healthy cash flow and perceived undervaluation suggest solid potential for investors seeking exposure to sustainable asset management.

About Impax Asset Management

Impax Asset Management Group plc is a specialist investment firm dedicated to advancing the transition toward a more sustainable global economy. Listed on London’s AIM market, the company provides discretionary and advisory investment management services focused on environmental, social, and governance (ESG) principles. Through its thematic investment strategies, Impax aims to generate long-term value by identifying opportunities arising from the shift to sustainability across global industries.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Fusion Antibodies plc (LSE:FAB) has secured a significant new multi-target Integrated Therapeutic Antibody Services contract with a global pharmaceutical company based in Europe. The project focuses on the humanisation of VHH antibody fragments, reflecting Fusion’s strategic commitment to partnering with leading pharmaceutical firms to strengthen its market position and support sustainable growth. Expected to be completed within the current financial year, the project is projected to generate revenues of at least £175,000 and reinforces Fusion’s reputation for delivering advanced, high-quality antibody solutions.

Despite this commercial achievement, Fusion Antibodies Plc continues to face financial challenges, including ongoing losses and cash flow constraints. While technical indicators point toward a mildly positive trend, weak valuation metrics continue to weigh on the company’s outlook. With limited updates from corporate events or earnings calls, financial and technical factors remain the primary influences on near-term performance.

About Fusion Antibodies Plc

Fusion Antibodies plc is a Belfast-based contract research organization (CRO) specializing in antibody engineering for therapeutic and diagnostic use. Founded in 2001 as a spin-out from Queen’s University Belfast, the company provides a full suite of services including antibody discovery, design, production, and optimization. With a global client base that includes several top-tier pharmaceutical companies, Fusion aims to accelerate drug development through innovative scientific platforms and cutting-edge engineering solutions.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Bloomsbury Publishing (LSE:BMY) has revealed a landmark multi-film agreement between acclaimed author Katherine Rundell and Disney, centered on her hit Impossible Creatures book series. The partnership includes film rights and a first-look development arrangement with Rundell’s production company, Impossible Films, paving the way for the series to evolve into a major cinematic franchise. This collaboration not only underscores the growing global appeal of Impossible Creatures but also strengthens Bloomsbury’s strategic foothold in the fantasy and entertainment markets.

The deal follows Bloomsbury’s continued financial strength, underpinned by steady revenue growth, a solid balance sheet, and an appealing dividend yield. While short-term technical indicators suggest minor weakness, the company’s overall financial health and valuation remain sound, supporting a positive long-term outlook.

About Bloomsbury Publishing

Bloomsbury Publishing Plc is a leading independent publisher recognized for its extensive catalog of print, ebook, and audio titles across fiction and non-fiction. Operating primarily in the UK, Europe, and Commonwealth markets, the company has built a strong reputation for nurturing bestselling authors, including Katherine Rundell, whose partnership with Bloomsbury began in 2015. Through its blend of literary excellence and strategic media collaborations, Bloomsbury continues to expand its influence across global publishing and entertainment.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Aptamer Group (LSE:APTA) has secured a substantial £360,000 agreement with one of the world’s top three pharmaceutical companies to develop Optimer® binders for targeted radiopharmaceutical applications, including potential therapeutic uses. This deal marks an important step into the rapidly growing US$7.5 billion targeted radiopharmaceuticals market and could open the door to future licensing and royalty opportunities.

In addition to this flagship contract, Aptamer has signed a further £665,000 in new agreements and project extensions. These include collaborations with a top five global pharmaceutical company and a therapeutic partnership with Invizius. Together, these projects have helped build a strong sales pipeline valued at £3.4 million, providing a solid foundation for revenue growth in the current fiscal year.

Despite these commercial wins, Aptamer Group Plc continues to face financial headwinds. Persistent losses, debt reliance, and weak technical indicators weigh on its short-term outlook. However, the company’s expanding portfolio of partnerships and growing presence in high-value life sciences markets offer encouraging signs for long-term growth potential.

About Aptamer Group Plc

Aptamer Group is a biotechnology company developing next-generation synthetic binders—known as Optimer® binders—for use across the life sciences sector. Designed as advanced alternatives to antibodies, Optimer® binders offer enhanced stability, lower production costs, and broad applications in therapeutics, diagnostics, and research. Operating primarily through a fee-for-service model, the company collaborates with leading pharmaceutical partners to develop custom Optimer® assets, building a foundation for future licensing revenues. Founded in 2008 and headquartered in York, UK, Aptamer Group is listed on the AIM market of the London Stock Exchange.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Netcall (LSE:NET) has delivered record financial results for the year ended June 2025, fueled by surging demand for its digital automation and artificial intelligence solutions. The company’s total revenue climbed 23% to £48.0 million, while cloud services revenue surged 48%. The Liberty platform’s cloud annual contract value (ACV) jumped 52%, now representing 80% of the company’s total ACV. Netcall also completed its cloud investment program, significantly enhancing its AI capabilities and expanding its customer base. These developments have resulted in a record sales pipeline and a contracted revenue order book of £79 million. The successful integration of its recent acquisitions, Govtech and Parble, has further extended its market presence—especially in the public sector and local government space.

While Netcall’s robust financial performance and strategic progress support a positive outlook, its high valuation and overbought technical indicators warrant some caution. The company remains well-positioned for continued growth, though investors should remain mindful of potential valuation risks.

About Netcall

Netcall Plc is a UK-based enterprise software provider that unites automation, AI, and customer engagement in a single platform. Its flagship Liberty platform streamlines customer interactions and digitizes workflows for roughly 600 organizations across industries such as healthcare, government, and financial services. The company’s client portfolio includes two-thirds of NHS Acute Health Trusts and major corporations like Legal & General, Baloise, and Santander. Through its focus on intelligent automation, Netcall continues to drive digital transformation and operational efficiency for its customers.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Seeing Machines Limited (LSE:SEE) has received a US$1.8 million purchase order for its Guardian Backup-driver Monitoring System (BdMS) from a major autonomous vehicle company in North America. The contract will support the customer’s expansion of its autonomous test fleet across the United States, underscoring the essential role of Seeing Machines’ technology in maintaining safety as the industry moves toward fully autonomous transportation. The Guardian BdMS plays a key part in bridging the gap between human oversight and self-driving systems, strengthening Seeing Machines’ position within the rapidly growing autonomous ride-hailing sector.

Despite its technological leadership, the company’s financial outlook remains mixed. Seeing Machines continues to report strong revenue growth but faces ongoing challenges with profitability and cash flow. Technical indicators suggest a neutral to slightly positive momentum, though valuation remains under pressure due to negative earnings and the absence of dividend payouts. With limited updates from corporate events or earnings calls, these financial factors primarily shape the company’s short-term outlook.

About Seeing Machines

Founded in 2000 and headquartered in Australia, Seeing Machines Limited is a global pioneer in vision-based monitoring systems powered by artificial intelligence. The company develops advanced operator monitoring solutions designed to enhance safety across multiple sectors, including automotive, commercial transport, off-road machinery, and aviation. Its technology integrates AI algorithms, embedded processing, and optical systems to deliver real-time insights into driver and operator behavior, contributing to safer and more efficient transport worldwide.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

East Star Resources (LSE:EST) has announced encouraging exploration results from its Snowy epithermal gold project in Kazakhstan. The company has pinpointed a highly prospective epithermal gold target, with surface rock chip samples confirming the presence of gold and a vein system extending more than 100 meters. Geological evidence suggests that the mineralization fits a low-sulphidation epithermal model, comparable to major deposits found in other parts of the world—indicating the potential for a sizable gold system.

Building on these findings, East Star Resources plans to conduct further mapping and sampling to refine its understanding of the target area and prepare for possible drilling. This initiative underscores the company’s commitment to expanding its exploration footprint and strengthening its resource portfolio.

About East Star Resources

East Star Resources Plc is a mineral exploration company dedicated to discovering and developing copper and gold deposits in Kazakhstan. The company employs diverse exploration approaches, including volcanogenic massive sulphide (VMS), copper porphyry, and epithermal gold exploration programs. Supported by local geological expertise and a grant from BHP Xplor, East Star Resources continues to advance its strategy of identifying high-potential mineral assets across the region.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.